| HOME >> BIOLOGY >> TECHNOLOGY |
SAN DIEGO, Calif., Sept. 8, 2011 /PRNewswire/ -- HUYA Bioscience International, a leader in globalizing China's pharmaceutical innovations, today announced a strategic partnership with the Zhejiang Chinese Medical University Life Science College. The collaboration agreement will accelerate the global drug development of China's novel Traditional Chinese Medicines (TCM).
The partnership is expected to bring productive synergy between the two parties. Zhejiang Chinese Medical University Life Science College, a prominent traditional Chinese medicine university in southern China, is recognized for its strength in leading-edge research in TCM. HUYA has a strong commitment toward developing novel therapeutics from TCM in areas of unmet medical needs. HBI-3000, HUYA's novel anti-arrhythmic compound currently in development in both China and the U.S., was originally derived from a TCM.
HUYA is one of the first companies to have recognized China's potential to help meet the global need for new preclinical and clinical stage compounds. The company is committed to facilitating and promoting the global development and commercialization of novel pharmaceutical products originating in China. HUYA has established a series of collaborations with leading universities and research institutions throughout China and has pioneered in-licensing innovative compounds from the country, utilizing its expertise to advance these compounds for global markets.
"The alliance with Zhejiang Chinese Medical University Life Science College will further strengthen HUYA's collaborative efforts with the faculty and researchers of the university," said Clement Gingras, HUYA's CTO and COO, China. "Together, HUYA and Zhejiang Chinese Medical University Life Science College will help advance the progression of TCM to the global markets, benefiting patients worldwide."
Dr. Zhishan Ding, Associate Dean of Zhejiang Chinese Medical University Life Science Colleg
'/>"/>
| SOURCE HUYA Bioscience International Copyright©2010 PR Newswire. All rights reserved |